Risk of Anaplastic Large Cell Lymphoma Following Postmastectomy Implant Reconstruction in Women With Breast Cancer and Ductal Carcinoma in Situ

Connor J Kinslow; David M DeStephano; Christine H Rohde; Lisa A Kachnic; Simon K Cheng; Alfred I Neugut; David P Horowitz

doi:10.1001/jamanetworkopen.2022.43396

Risk of Anaplastic Large Cell Lymphoma Following Postmastectomy Implant Reconstruction in Women With Breast Cancer and Ductal Carcinoma in Situ

JAMA Netw Open. 2022 Nov 1;5(11):e2243396. doi: 10.1001/jamanetworkopen.2022.43396.

Authors

Connor J Kinslow^{1

2}, David M DeStephano^{1

2}, Christine H Rohde^{2

3}, Lisa A Kachnic^{1

2}, Simon K Cheng^{1

2}, Alfred I Neugut^{2

4

5}, David P Horowitz^{1

2}

Affiliations

¹ Department of Radiation Oncology, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York.
² Herbert Irving Comprehensive Cancer Center, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York.
³ Division of Plastic and Reconstructive Surgery, Department of Surgery, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York.
⁴ Department of Medicine, Vagelos College of Physicians and Surgeons, New York, New York.
⁵ Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York.

No abstract available

Plain language summary

This cohort study examines the risk of anaplastic large cell lymphoma (ALCL) following postmastectomy implant reconstruction among US women with breast cancer and ductal carcinoma in situ (DCIS).

MeSH terms

Breast Neoplasms* / pathology
Breast Neoplasms* / surgery
Carcinoma, Intraductal, Noninfiltrating* / pathology
Female
Humans
Lymphoma, Large-Cell, Anaplastic* / etiology
Lymphoma, Large-Cell, Anaplastic* / surgery
Mammaplasty* / adverse effects
Mastectomy / adverse effects